Shenzhen Salubris Pharmaceuticals Co., Ltd. [002294.SZ] Stock Forecast

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines for cardiovascular, anti-diabetic, antineoplastic, and orthopedic therapeutic in China. It offers cardiovascular and cerebrovascular products, such as allisartan isoproxil, benazepril hydrochloride, desloratadine, and clopidogrel bisulfate tablets, as well as bivalirudin and pamidronate disodium injections; recombinant SeV-hFGF2/dF Injection for the treatment of diabetic foot disease; and anti-tumor and orthopedics medicines. The company also provides anti-infection products comprising cefonicid sodium, ceftazidime, ceftriaxone sodium, cefonicid sodium, cefminox sodium, cefuroxime sodium, cefepime hydrochloride, and cefodizime sodium injections, as well as azithromycin dispersible and levetiracetam tablets. In addition, it offers biotechnological drugs, such as recombinant protein and monoclonal antibody drugs. Further, the company is involved in import, licensing-in, and licensing-out medicines for Europe markets. The company was founded in 1998 and is headquartered in Shenzhen, China.